ライフサイエンスコーパス: progestagen

1 nformation about other types of oestrogen or progestagen.

2 ments for hot flushes include oestrogens and progestagens.

3 8 (0.66-2.17) for the other third-generation progestagens.

4 in users of OCs containing second-generation progestagens.

5 only (1.30 [1.21-1.40], p<0.0001), oestrogen-progestagen (2.00 [1.88-2.12], p<0.0001), and tibolone (

6 ine disruptors (EDs), oestrogens, androgens, progestagens and glucocorticoids.

7 easing hormone analogues, danazol, and depot progestagens are associated with a higher incidence of a

8 ins (also called gestagens, progestogens, or progestagens) are used today in assisting a range of med

9 nally, two secreted proteins, galectin-1 and progestagen-associated protein 14, known to have immunom

10 ffect is substantially greater for oestrogen-progestagen combinations than for other types of HRT.

11 ditional cancers per 1000 users of oestrogen-progestagen combinations.

12 Additionally, the combined oestrogen-progestagen contraceptive pill might decrease lamotrigin

13 ate that reproductive hormones, specifically progestagens, contribute to the shifts in the gut microb

14 a combined therapy of oestrogen with cyclic progestagen (eg. medroxyprogesterone acetate) had a rela

15 ptives (OCs) containing the third-generation progestagens gestodene or desogestrel than in users of O

16 ed oral contraceptives (containing oestrogen+progestagen) has been associated with a small increase i

17 d recruited healthy women.Combined oestrogen/progestagen HRT was used in three trials and oestrogen a

18 ho are not on hormone replacement, even when progestagen is added for 10 or more days per month.

19 se combined therapy of oestrogen with cyclic progestagen on a long-term basis have an increased risk

20 impact of a regimen of oestrogen with cyclic progestagen on risk of endometrial cancer for postmenopa

21 on the association between current or recent progestagen-only contraceptive use and breast cancer ris

22 Progestagen-only contraceptive use is increasing, but in

23 ociated with 5 years use of oral combined or progestagen-only contraceptives in high-income countries

24 t new evidence that current or recent use of progestagen-only contraceptives is associated with a sli

25 ive risks (RRs) for current or recent use of progestagen-only contraceptives: oral = 1.29 (95% CI [1.

26 criteria for VTE, two of whom were users of progestagen-only OCs.

27 About half the prescriptions were for progestagen-only preparations.

28 ed results from 12 observational studies for progestagen-only preparations.

29 enopausal women, with particular emphasis on progestagen-only preparations.

30 ive prescription was for oral combined, oral progestagen-only, injected progestagen, or progestagen-r

31 aried little between specific oestrogens and progestagens or their doses; or between continuous and s

32 al combined, oral progestagen-only, injected progestagen, or progestagen-releasing intrauterine devic

33 Among women with fewer than 10 days of added progestagen per month, the relative risk was 3.1 (1.7-5.

34 from individuals using androgen or androgen-progestagen regimens.

35 l progestagen-only, injected progestagen, or progestagen-releasing intrauterine devices (IUDs): ORs =

36 risk was substantially greater for oestrogen-progestagen than for other types of HRT (p<0.0001).

37 Among users of third-generation progestagens, the risk of VTE was higher in users of des

38 ast cancers, 15000 associated with oestrogen-progestagen; the extra deaths cannot yet be reliably est

39 erapy (p=0.0001), and for users of oestrogen-progestagen therapy (p<0.0001).

40 cancer were generally greater for oestrogen-progestagen therapy than for oestrogen-only therapy, and

41 reas that for women with 10-21 days of added progestagen was 1.3 (0.8-2.2).

42 s from this study suggest that environmental progestagens will lead to defeminization at environmenta